Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05675787
PHASE2

Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia

Sponsor: Peking University People's Hospital

View on ClinicalTrials.gov

Summary

To explore the treatment efficacy of medroxyprogesterone acetate plus atorvastatin in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.

Official title: Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Atypical Endometrial Hyperplasia and Early Endometrial Carcinoma

Key Details

Gender

FEMALE

Age Range

17 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

82

Start Date

2023-01-06

Completion Date

2025-10-31

Last Updated

2024-07-11

Healthy Volunteers

No

Interventions

DRUG

Medroxyprogesterone acetate + Atorvastatin

MPA (at a dosage of 250-500 mg/day,) + Atorvastatin (at a dosage of 20 mg/day), by mouth,

Locations (1)

Wang Jianliu

Beijing, Beijing Municipality, China